Treatment of Locally Advanced Head and Neck Cancer: Historical and Critical Review

Muhyi Al-Sarraf, MD, FRCPC, FACP

Disclosures

Cancer Control. 2002;9(5) 

In This Article

Conclusions

Considerable progress has been made in the treatment results of patients with locally advanced head and neck cancers. This has resulted in a decrease in distant involvement and improvements in local control, quality of life (with organ preservation), disease-free survival, and overall survival. These endpoints have been demonstrated not only in carefully designed phase III trials and meta-analyses, but also -- and more significantly -- in the changes in the natural history of this disease as shown on the national level, especially in patients with advanced nasopharyngeal cancer. The use of "total" chemotherapy-radiation therapy treatment, the appropriate application of the newer chemotherapy active agents, and the inclusion of the biological and the specific targeted compounds as part of therapy in these patients should provide further improvement in treatment outcomes.

This article was originally certified for CME credit. For accreditation details, contact the publisher.
H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, Tampa, FL 33612. Telephone: (813) 632-1349. Fax: (813) 903-4950. Email: ccjournal@moffitt.usf.edu. Cancer Control is included in Index Medicus/MEDLINE and EMBASE/Excerpta Medica.)

As a sponsor accredited by the Accreditation Council for Continuing Medical Education, the University of South Florida College of Medicine must insure balance, independence, objectivity and scientific rigor in all its individually sponsored or jointly sponsored educational activities. Faculty participating in a sponsored activity are expected to disclose to the activity audience any significant financial interest or other relationship (1) with the manufacturer(s) of any commercial product(s) and (2) with any commercial supporters of the activity. (Significant financial interest or other relationship can include such things as grants or research support, employee, consultant, major stock holder, member of speaker's bureau, etc.). The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....